Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Other Non-Current Assets (2020 - 2025)

Ovid Therapeutics (OVID) has disclosed Other Non-Current Assets for 6 consecutive years, with $1.9 million as the latest value for Q1 2025.

  • For the quarter ending Q1 2025, Other Non-Current Assets rose 1009.77% year-over-year to $1.9 million, compared with a TTM value of $1.9 million through Mar 2025, up 1009.77%, and an annual FY2024 reading of $92000.0, down 56.19% over the prior year.
  • Other Non-Current Assets was $1.9 million for Q1 2025 at Ovid Therapeutics, up from $92000.0 in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $1.9 million in Q3 2024 and bottomed at $92000.0 in Q4 2024.
  • Average Other Non-Current Assets over 5 years is $714652.9, with a median of $261191.0 recorded in 2022.
  • The sharpest move saw Other Non-Current Assets soared 1823.73% in 2023, then plummeted 90.99% in 2024.
  • Year by year, Other Non-Current Assets stood at $260126.0 in 2021, then rose by 0.41% to $261191.0 in 2022, then decreased by 19.6% to $210000.0 in 2023, then tumbled by 56.19% to $92000.0 in 2024, then skyrocketed by 1998.91% to $1.9 million in 2025.
  • Business Quant data shows Other Non-Current Assets for OVID at $1.9 million in Q1 2025, $92000.0 in Q4 2024, and $1.9 million in Q3 2024.